List of Torisel drug patents
Torisel is owned by Pf Prism Cv.
Torisel contains Temsirolimus.
Torisel has a total of 10 drug patents out of which 0 drug patents have expired.
Torisel was authorised for market use on 30 May, 2007.
Torisel is available in solution;intravenous dosage forms.
Torisel can be used as method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus..
The generics of Torisel are possible to be released after 10 November, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(3 months from now) | |
| US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(3 months from now) | |
| US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(3 months from now) | |
|
US8299116
(Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(9 months from now) | |
|
US8455539
(Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(9 months from now) | |
|
US8722700
(Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(9 months from now) | |
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(2 years from now) | |
|
US8026276
(Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(3 years from now) | |
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(9 years from now) | |
|
US8791097
(Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(9 years from now) | |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
TORISEL family patents
9
United States
6
European Union
4
Japan
3
Denmark
3
Australia
3
Slovenia
3
Portugal
3
Spain
3
Korea, Republic of
3
China
2
Israel
2
South Africa
2
Mexico
2
Russia
2
Hungary
2
Argentina
2
Croatia
2
Brazil
2
Cyprus
2
Poland
2
Taiwan, Province of China
2
Canada
1
Austria
1
Hong Kong
1
Norway
1
Costa Rica
1
Germany
1
Colombia
1
Chile
1
Ecuador
1
Ukraine
1
Panama
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic